q32851 vectastain abc kit vector laboratories (Vector Laboratories)
Vector Laboratories is a verified supplier 
Vector Laboratories manufactures this product 
96
Structured Review
Vector Laboratories
q32851 vectastain abc kit vector laboratories
Q32851 Vectastain Abc Kit Vector Laboratories, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 96/100, based on 16796 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/q32851+vectastain+abc+kit+vector+laboratories/VECTASTAIN+Elite+ABC+HRP+Kit+(Peroxidase%2C+Universal)/10__1016_slash_j__ccell__2025__07__015-821-319-323
Average 96 stars, based on 16796 article reviews
Q32851 Vectastain Abc Kit Vector Laboratories, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 96/100, based on 16796 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/q32851+vectastain+abc+kit+vector+laboratories/VECTASTAIN+Elite+ABC+HRP+Kit+(Peroxidase%2C+Universal)/10__1016_slash_j__ccell__2025__07__015-821-319-323
Average 96 stars, based on 16796 article reviews
q32851 vectastain abc kit vector laboratories - by Bioz Stars,
2026-10
96/100 stars
Images
Related Articles
Recombinant:Article Title: Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer Article Snippet: Article Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer Graphical abstract Highlights • Cyclic STAT3 decoy (CS3D) inhibits murine HNSCC tumors via CD8+ cells • CS3D is well tolerated in a clinical trial of pet cats with oral cancer • CS3D induces a 35% disease control rate in pet cats with oral cancer • Analysis of the clinical trial specimens identifies potential predictive biomarkers Authors Jennifer R. Grandis, Katherine A. Skorupski, Ning Cheng, ..., Adam B. Olshen, Ellen E. Sparger, Daniel E. Johnson Correspondence jennifer.grandis@ucsf.edu (J.R.G.), daniel.johnson@ucsf.edu (D.E.J.). In brief Grandis et al. evaluate the activity of a cyclic oligonucleotide inhibitor of STAT3, CS3D, in immunocompetent models of mouse head and neck cancer and in a clinical trial of pet cats with oral cancer.. CS3D has low toxicity and modulation of immune parameters is associated with anti-tumor activity. Saline:Article Title: Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer Article Snippet: Article Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer Graphical abstract Highlights • Cyclic STAT3 decoy (CS3D) inhibits murine HNSCC tumors via CD8+ cells • CS3D is well tolerated in a clinical trial of pet cats with oral cancer • CS3D induces a 35% disease control rate in pet cats with oral cancer • Analysis of the clinical trial specimens identifies potential predictive biomarkers Authors Jennifer R. Grandis, Katherine A. Skorupski, Ning Cheng, ..., Adam B. Olshen, Ellen E. Sparger, Daniel E. Johnson Correspondence jennifer.grandis@ucsf.edu (J.R.G.), daniel.johnson@ucsf.edu (D.E.J.). In brief Grandis et al. evaluate the activity of a cyclic oligonucleotide inhibitor of STAT3, CS3D, in immunocompetent models of mouse head and neck cancer and in a clinical trial of pet cats with oral cancer.. CS3D has low toxicity and modulation of immune parameters is associated with anti-tumor activity. Lysis:Article Title: Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer Article Snippet: Article Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer Graphical abstract Highlights • Cyclic STAT3 decoy (CS3D) inhibits murine HNSCC tumors via CD8+ cells • CS3D is well tolerated in a clinical trial of pet cats with oral cancer • CS3D induces a 35% disease control rate in pet cats with oral cancer • Analysis of the clinical trial specimens identifies potential predictive biomarkers Authors Jennifer R. Grandis, Katherine A. Skorupski, Ning Cheng, ..., Adam B. Olshen, Ellen E. Sparger, Daniel E. Johnson Correspondence jennifer.grandis@ucsf.edu (J.R.G.), daniel.johnson@ucsf.edu (D.E.J.). In brief Grandis et al. evaluate the activity of a cyclic oligonucleotide inhibitor of STAT3, CS3D, in immunocompetent models of mouse head and neck cancer and in a clinical trial of pet cats with oral cancer.. CS3D has low toxicity and modulation of immune parameters is associated with anti-tumor activity. Protease Inhibitor:Article Title: Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer Article Snippet: Article Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer Graphical abstract Highlights • Cyclic STAT3 decoy (CS3D) inhibits murine HNSCC tumors via CD8+ cells • CS3D is well tolerated in a clinical trial of pet cats with oral cancer • CS3D induces a 35% disease control rate in pet cats with oral cancer • Analysis of the clinical trial specimens identifies potential predictive biomarkers Authors Jennifer R. Grandis, Katherine A. Skorupski, Ning Cheng, ..., Adam B. Olshen, Ellen E. Sparger, Daniel E. Johnson Correspondence jennifer.grandis@ucsf.edu (J.R.G.), daniel.johnson@ucsf.edu (D.E.J.). In brief Grandis et al. evaluate the activity of a cyclic oligonucleotide inhibitor of STAT3, CS3D, in immunocompetent models of mouse head and neck cancer and in a clinical trial of pet cats with oral cancer.. CS3D has low toxicity and modulation of immune parameters is associated with anti-tumor activity. MTT Assay:Article Title: Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer Article Snippet: Article Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer Graphical abstract Highlights • Cyclic STAT3 decoy (CS3D) inhibits murine HNSCC tumors via CD8+ cells • CS3D is well tolerated in a clinical trial of pet cats with oral cancer • CS3D induces a 35% disease control rate in pet cats with oral cancer • Analysis of the clinical trial specimens identifies potential predictive biomarkers Authors Jennifer R. Grandis, Katherine A. Skorupski, Ning Cheng, ..., Adam B. Olshen, Ellen E. Sparger, Daniel E. Johnson Correspondence jennifer.grandis@ucsf.edu (J.R.G.), daniel.johnson@ucsf.edu (D.E.J.). In brief Grandis et al. evaluate the activity of a cyclic oligonucleotide inhibitor of STAT3, CS3D, in immunocompetent models of mouse head and neck cancer and in a clinical trial of pet cats with oral cancer.. CS3D has low toxicity and modulation of immune parameters is associated with anti-tumor activity. SYBR Green Assay:Article Title: Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer Article Snippet: Article Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer Graphical abstract Highlights • Cyclic STAT3 decoy (CS3D) inhibits murine HNSCC tumors via CD8+ cells • CS3D is well tolerated in a clinical trial of pet cats with oral cancer • CS3D induces a 35% disease control rate in pet cats with oral cancer • Analysis of the clinical trial specimens identifies potential predictive biomarkers Authors Jennifer R. Grandis, Katherine A. Skorupski, Ning Cheng, ..., Adam B. Olshen, Ellen E. Sparger, Daniel E. Johnson Correspondence jennifer.grandis@ucsf.edu (J.R.G.), daniel.johnson@ucsf.edu (D.E.J.). In brief Grandis et al. evaluate the activity of a cyclic oligonucleotide inhibitor of STAT3, CS3D, in immunocompetent models of mouse head and neck cancer and in a clinical trial of pet cats with oral cancer.. CS3D has low toxicity and modulation of immune parameters is associated with anti-tumor activity. Transfection:Article Title: Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer Article Snippet: Article Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer Graphical abstract Highlights • Cyclic STAT3 decoy (CS3D) inhibits murine HNSCC tumors via CD8+ cells • CS3D is well tolerated in a clinical trial of pet cats with oral cancer • CS3D induces a 35% disease control rate in pet cats with oral cancer • Analysis of the clinical trial specimens identifies potential predictive biomarkers Authors Jennifer R. Grandis, Katherine A. Skorupski, Ning Cheng, ..., Adam B. Olshen, Ellen E. Sparger, Daniel E. Johnson Correspondence jennifer.grandis@ucsf.edu (J.R.G.), daniel.johnson@ucsf.edu (D.E.J.). In brief Grandis et al. evaluate the activity of a cyclic oligonucleotide inhibitor of STAT3, CS3D, in immunocompetent models of mouse head and neck cancer and in a clinical trial of pet cats with oral cancer.. CS3D has low toxicity and modulation of immune parameters is associated with anti-tumor activity. Reverse Transcription:Article Title: Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer Article Snippet: Article Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer Graphical abstract Highlights • Cyclic STAT3 decoy (CS3D) inhibits murine HNSCC tumors via CD8+ cells • CS3D is well tolerated in a clinical trial of pet cats with oral cancer • CS3D induces a 35% disease control rate in pet cats with oral cancer • Analysis of the clinical trial specimens identifies potential predictive biomarkers Authors Jennifer R. Grandis, Katherine A. Skorupski, Ning Cheng, ..., Adam B. Olshen, Ellen E. Sparger, Daniel E. Johnson Correspondence jennifer.grandis@ucsf.edu (J.R.G.), daniel.johnson@ucsf.edu (D.E.J.). In brief Grandis et al. evaluate the activity of a cyclic oligonucleotide inhibitor of STAT3, CS3D, in immunocompetent models of mouse head and neck cancer and in a clinical trial of pet cats with oral cancer.. CS3D has low toxicity and modulation of immune parameters is associated with anti-tumor activity. Viability Assay:Article Title: Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer Article Snippet: Article Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer Graphical abstract Highlights • Cyclic STAT3 decoy (CS3D) inhibits murine HNSCC tumors via CD8+ cells • CS3D is well tolerated in a clinical trial of pet cats with oral cancer • CS3D induces a 35% disease control rate in pet cats with oral cancer • Analysis of the clinical trial specimens identifies potential predictive biomarkers Authors Jennifer R. Grandis, Katherine A. Skorupski, Ning Cheng, ..., Adam B. Olshen, Ellen E. Sparger, Daniel E. Johnson Correspondence jennifer.grandis@ucsf.edu (J.R.G.), daniel.johnson@ucsf.edu (D.E.J.). In brief Grandis et al. evaluate the activity of a cyclic oligonucleotide inhibitor of STAT3, CS3D, in immunocompetent models of mouse head and neck cancer and in a clinical trial of pet cats with oral cancer.. CS3D has low toxicity and modulation of immune parameters is associated with anti-tumor activity. Staining:Article Title: Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer Article Snippet: Article Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer Graphical abstract Highlights • Cyclic STAT3 decoy (CS3D) inhibits murine HNSCC tumors via CD8+ cells • CS3D is well tolerated in a clinical trial of pet cats with oral cancer • CS3D induces a 35% disease control rate in pet cats with oral cancer • Analysis of the clinical trial specimens identifies potential predictive biomarkers Authors Jennifer R. Grandis, Katherine A. Skorupski, Ning Cheng, ..., Adam B. Olshen, Ellen E. Sparger, Daniel E. Johnson Correspondence jennifer.grandis@ucsf.edu (J.R.G.), daniel.johnson@ucsf.edu (D.E.J.). In brief Grandis et al. evaluate the activity of a cyclic oligonucleotide inhibitor of STAT3, CS3D, in immunocompetent models of mouse head and neck cancer and in a clinical trial of pet cats with oral cancer.. CS3D has low toxicity and modulation of immune parameters is associated with anti-tumor activity. Conjugation Assay:Article Title: Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer Article Snippet: Article Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer Graphical abstract Highlights • Cyclic STAT3 decoy (CS3D) inhibits murine HNSCC tumors via CD8+ cells • CS3D is well tolerated in a clinical trial of pet cats with oral cancer • CS3D induces a 35% disease control rate in pet cats with oral cancer • Analysis of the clinical trial specimens identifies potential predictive biomarkers Authors Jennifer R. Grandis, Katherine A. Skorupski, Ning Cheng, ..., Adam B. Olshen, Ellen E. Sparger, Daniel E. Johnson Correspondence jennifer.grandis@ucsf.edu (J.R.G.), daniel.johnson@ucsf.edu (D.E.J.). In brief Grandis et al. evaluate the activity of a cyclic oligonucleotide inhibitor of STAT3, CS3D, in immunocompetent models of mouse head and neck cancer and in a clinical trial of pet cats with oral cancer.. CS3D has low toxicity and modulation of immune parameters is associated with anti-tumor activity. |